SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-022876
Filing Date
2023-02-02
Accepted
2023-02-02 17:23:01
Documents
12
Period of Report
2023-01-31
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d344481d8k.htm   iXBRL 8-K 33561
  Complete submission text file 0001193125-23-022876.txt   159266

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA evlo-20230131.xsd EX-101.SCH 2840
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE evlo-20230131_lab.xml EX-101.LAB 17977
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evlo-20230131_pre.xml EX-101.PRE 11251
6 EXTRACTED XBRL INSTANCE DOCUMENT d344481d8k_htm.xml XML 3345
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 23582344
SIC: 2834 Pharmaceutical Preparations